
Phase Ib trial complete in patients with diabetic retinopathy
Breye Therapeutics is a clinical-stage ophthalmology focused biopharmaceutical company developing oral therapeutics for the early treatment of vascular eye diseases. The company has now completed its Phase Ib clinical trial evaluating its lead candidate, danegaptide, in patients with non-proliferative diabetic retinopathy (NPDR) with associated oedema. Read More













